C4 Therapeutics reported earnings of -$ 0.16 per CCCC share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.19 |
| Earnings Per Share (Surprise) | -$ 0.16 (+$ 0.0345) |
| Last Year's EPS | -$ 0.35 |
| EPS YoY Change |
Out of the last 33 earnings reporting periods, C4 Therapeutics beat analysts’ expectations 18 times and fell short of expectations 8 time(s). C4 Therapeutics reported earnings per share of -$ 0.16 in the last report surpassing an estimated EPS of -$ 0.19 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.19 | -$ 0.16 | -$ 0.44 | |
| Aug 11, 2026 | -$ 0.23 | -$ 0.18 | -$ 0.37 | |
| May 12, 2026 | -$ 0.25 | -$ 0.20 | -$ 0.37 | |
| Feb 26, 2026 | -$ 0.31 | -$ 0.18 | -$ 0.37 | |
| Nov 6, 2025 | -$ 0.41 | -$ 0.44 | -$ 0.49 | |
| Aug 7, 2025 | -$ 0.38 | -$ 0.37 | -$ 0.35 | |
| May 7, 2025 | -$ 0.48 | -$ 0.37 | -$ 0.26 | |
| May 6, 2025 | -$ 0.48 | -$ 0.37 | -$ 0.41 | |
| Feb 27, 2025 | -$ 0.45 | -$ 0.49 | -$ 0.68 | |
| Oct 31, 2024 | -$ 0.38 | -$ 0.35 | -$ 0.70 | |
| Aug 1, 2024 | -$ 0.37 | -$ 0.26 | -$ 0.52 | |
| May 8, 2024 | -$ 0.41 | -$ 0.41 | -$ 0.73 | |
| Feb 22, 2024 | -$ 0.67 | -$ 0.68 | -$ 0.71 | |
| Feb 21, 2024 | -$ 0.68 | -$ 0.70 | -$ 0.77 | |
| Nov 1, 2023 | -$ 0.66 | -$ 0.52 | -$ 0.65 | |
| Aug 8, 2023 | -$ 0.69 | -$ 0.73 | -$ 0.56 | |
| May 4, 2023 | -$ 0.75 | -$ 0.71 | -$ 0.65 | |
| Feb 23, 2023 | -$ 0.74 | -$ 0.77 | -$ 0.31 | |
| Nov 3, 2022 | -$ 0.67 | -$ 0.65 | -$ 0.51 | |
| Aug 4, 2022 | -$ 0.69 | -$ 0.56 | -$ 0.51 |
C4 Therapeutics’s stock was trading at $ 3.12 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, CCCC’s price decreased to $ 3.10 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.16 | $ 3.12 | $ 3.10 | |
| Aug 11, 2026 | -$ 0.18 | $ 3.62 | $ 3.90 | |
| May 12, 2026 | -$ 0.20 | $ 3.17 | $ 3.68 | |
| Feb 26, 2026 | -$ 0.18 | $ 2.77 | $ 2.70 | |
| Nov 6, 2025 | -$ 0.44 | $ 2.37 | $ 2.34 | |
| Aug 7, 2025 | -$ 0.37 | $ 1.96 | $ 2.50 | |
| May 7, 2025 | -$ 0.37 | $ 1.41 | $ 1.54 | |
| May 6, 2025 | -$ 0.37 | $ 1.62 | $ 1.50 | |
| Feb 27, 2025 | -$ 0.49 | $ 2.65 | $ 2.71 | |
| Oct 31, 2024 | -$ 0.35 | $ 5.53 | $ 5.61 | |
| Aug 1, 2024 | -$ 0.26 | $ 6.70 | $ 6.42 | |
| May 8, 2024 | -$ 0.41 | $ 6.79 | $ 6.80 | |
| Feb 22, 2024 | -$ 0.68 | $ 7.25 | $ 8.99 | |
| Feb 21, 2024 | -$ 0.70 | $ 7.58 | $ 8.80 | |
| Nov 1, 2023 | -$ 0.52 | $ 1.49 | $ 1.40 | |
| Aug 8, 2023 | -$ 0.73 | $ 3.52 | $ 3.46 | |
| May 4, 2023 | -$ 0.71 | $ 3.14 | $ 3.29 | |
| Feb 23, 2023 | -$ 0.77 | $ 5.92 | $ 5.33 | |
| Nov 3, 2022 | -$ 0.65 | $ 9.70 | $ 8.91 | |
| Aug 4, 2022 | -$ 0.56 | $ 10.94 | $ 12.77 |
C4 Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
C4 Therapeutics beat analysts’ expectations during the last earnings period by
